--- url: 'https://qubit.capital/blog/us-series-a-weekly-funding-roundup-week-5-march-2026' title: 'US Series A Weekly Funding Roundup (Mar 23-30, 2026): $320.0M Raised Across 4 Deals' author: name: Vaibhav Totuka url: 'https://qubit.capital/blog/author/vaibhav-totuka' date: '2026-03-30T06:03:29+05:30' modified: '2026-03-30T11:26:38+05:30' type: post summary: 'Four US Series A rounds closed this week totaling $320M, led by eMed''s $200M raise for GLP-1 telehealth and Latent Health''s $80M clinical AI round.' categories: - Weekly Funding Roundup image: 'https://qubit.capital/wp-content/uploads/2026/03/featured-us-series-a-64885.webp' published: true --- # US Series A Weekly Funding Roundup (Mar 23-30, 2026): $320.0M Raised Across 4 Deals US Series A activity this week was dominated by healthcare. Four deals closed for a combined $320 million, with two healthtech companies accounting for $280 million of that total. The headline number is inflated by eMed’s massive $200 million round, but even without it, the remaining three deals averaged $40 million, a healthy showing for the stage. The week’s pattern is clear: investors are betting big on AI applied to specific, regulation-heavy industries. Whether it’s GLP-1 medication management, clinical prior authorizations, or insurance operations, the common thread is AI systems built to navigate complex compliance requirements. That theme echoed across stages too. US seed deals pulled in $31.8 million across four rounds this week, while five later-stage US companies raised $327 million, suggesting broad confidence in the domestic startup market heading into Q2. Weekly Funding Roundup MAR 23-30, 2026 $320M TOTAL RAISED 4DEALS CLOSED 100%SERIES A $80MAVG DEAL SIZE USTOP REGION BY STAGE Series A$320M100% BY SECTOR eMedHealthtech$200M Latent HealthHealthtech$80M NotchFintech / AI$30M TraydSaaS / Construction Tech$10M Table of Contents - [1. eMed Raises $200M For AI-Driven GLP-1 Telehealth](#1-emed-raises-$200m-for-ai-driven-glp-1-telehealth) [Deal Overview](#deal-overview) - [Investor Profile](#investor-profile) - [Company and Leadership](#company-and-leadership) - [Problem and Opportunity](#problem-and-opportunity) - [Product and Technology](#product-and-technology) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision) - [Market Context](#market-context) - [2. Latent Health Raises $80M For Clinical AI](#2-latent-health-raises-$80m-for-clinical-ai) [Deal Overview](#deal-overview-1) - [Investor Profile](#investor-profile-1) - [Company and Leadership](#company-and-leadership-1) - [Problem and Opportunity](#problem-and-opportunity-1) - [Product and Technology](#product-and-technology-1) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-1) - [Market Context](#market-context-1) - [3. Notch Raises $30M For Regulated Industry AI](#3-notch-raises-$30m-for-regulated-industry-ai) [Deal Overview](#deal-overview-2) - [Investor Profile](#investor-profile-2) - [Company and Leadership](#company-and-leadership-2) - [Problem and Opportunity](#problem-and-opportunity-2) - [Product and Technology](#product-and-technology-2) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-2) - [Market Context](#market-context-2) - [4. Trayd Raises $10M For Construction Back-Office Automation](#4-trayd-raises-$10m-for-construction-back-office-automation) [Deal Overview](#deal-overview-3) - [Investor Profile](#investor-profile-3) - [Company and Leadership](#company-and-leadership-3) - [Problem and Opportunity](#problem-and-opportunity-3) - [Product and Technology](#product-and-technology-3) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-3) - [Market Context](#market-context-3) - [Lessons For Founders](#lessons-for-founders) ## 1. eMed Raises $200M For AI-Driven GLP-1 Telehealth ### Deal Overview - **Stage:** Series A - **Sector:** Healthtech - **Geography:** Miami, FL - **Round Size:** $200M - **Valuation:** $2B+ (unicorn status) ### Investor Profile This round drew an unusual investor mix. Aon Consulting anchored the raise, joined by a roster of high-profile individuals: Joe Lonsdale (Palantir co-founder, 8VC), Jeff Aronin (Paragon Biosciences founder), and Tom Ricketts (Cubs owner, TD Ameritrade family). Tom Brady, who joined as Chief Wellness Officer in January 2026, also participated. The celebrity and strategic investor composition reflects eMed’s employer-facing go-to-market, where brand recognition matters as much as technology. ### Company and Leadership [eMed](https://www.emed.com) was founded in 2020 by Michael Ferro and originally operated as an at-home COVID-19 testing platform. The company pivoted to GLP-1 and chronic disease management in 2024-2025. CEO Linda Yaccarino, formerly the CEO of X/Twitter, was appointed in August 2025. The company has served 3.7 million customers since its launch. ### Problem and Opportunity Employers are struggling with GLP-1 costs. Drugs like Ozempic and Wegovy can run $1,000+ per month per employee, and demand is surging. Most telehealth platforms sell directly to consumers, which means employers have no visibility into adherence, outcomes, or cost control. eMed targets that gap by packaging diagnostics, prescriptions, and ongoing coaching into a single employer-sponsored platform. ### Product and Technology The platform runs on what eMed calls “Empathetic AI,” an agentic system that handles remote diagnostic testing, identity verification, telehealth visits, prescription delivery, and adherence coaching. It’s an end-to-end pipeline from initial screening through ongoing GLP-1 treatment. The employer-focused model generates population health data that direct-to-consumer competitors don’t collect, giving eMed a feedback loop on clinical outcomes at scale. ### Use of Proceeds and Vision Funds will advance the AI platform, launch a capitated payment model to help employers manage healthcare costs, and expand into government payer segments. eMed is positioning itself as the default employer platform for population-scale chronic care management. ### Market Context The GLP-1 drug class is projected to reach $150 billion in annual global sales within the next decade. Multiple telehealth startups compete in this space, but most target individual consumers. eMed’s bet is that the real money sits with employers and payers who need cost containment alongside treatment access. ## 2. Latent Health Raises $80M For Clinical AI ### Deal Overview - **Stage:** Series A - **Sector:** Healthtech - **Geography:** San Francisco, CA - **Round Size:** $80M - **Valuation:** Not disclosed ### Investor Profile Spark Capital and Transformation Capital co-led the round, with General Catalyst, Y Combinator, Conviction, and McKesson Ventures participating. McKesson’s involvement is worth noting. As the largest pharmaceutical distributor in the US, their strategic interest signals that the medication access bottleneck is a recognized pain point across the supply chain. The jump from a $500K YC pre-seed to an $80 million Series A is among the steeper step-ups in recent healthcare AI funding. ### Company and Leadership [Latent Health](https://www.latenthealth.com) was founded in 2022 by Sriram Somasundaram and Rishabh Jain. Both are YC alumni. The company now partners with 45+ health systems, including Yale, Mayo Clinic, UCSF, and Mount Sinai, covering 50% of the top 20 US health systems and over 2 million patients. ### Problem and Opportunity Getting a medication approved through prior authorization can take hours of back-and-forth between hospitals, insurers, and pharmacies. Much of it still happens by phone and fax. This administrative friction delays patient access to drugs they’ve already been prescribed. The broader opportunity is staggering: $98 billion in annual US healthcare admin spending, with only 3% currently addressed by software. ### Product and Technology Latent Health built a Clinical Reasoning Engine that reads EHR data, interprets drug criteria, extracts relevant clinical evidence, and orchestrates the prior authorization workflow. Their models run at 97% clinical QA accuracy, outperforming GPT-4 and O3 on the same tasks. Training costs come in at roughly $14/hour versus $98/hour for general-purpose models, a 7x advantage. The system uses flexible multi-modal training across 7B-70B parameter models, keeping experimentation cycles 2-3x faster than competitors. ### Use of Proceeds and Vision The company will use the funds to add more health system partners, deepen connections across the hospital-payer-pharmacy chain, and scale its AI deployment infrastructure. The long-term goal is to eliminate the administrative delay between diagnosis and treatment. ### Market Context The prior authorization AI market exceeds $100 million and is growing at roughly 10x year-over-year. Latent Health sits at the intersection of clinical AI and workflow automation, two categories attracting heavy investment. Their proprietary clinical datasets from 45+ health systems create a network effect that widens with each new partnership. ## 3. Notch Raises $30M For Regulated Industry AI ### Deal Overview - **Stage:** Series A - **Sector:** Fintech / AI - **Geography:** New York, NY - **Round Size:** $30M - **Valuation:** Not disclosed ### Investor Profile Headline led the round with participation from Lightspeed Venture Partners, Jibe Ventures, Illuminate Financial, and Phoenix Insurance. The investor lineup blends pure venture (Headline, Lightspeed) with financial services specialists (Illuminate, Phoenix Insurance). Having an insurance carrier on the cap table validates Notch’s regulated-industry positioning and provides a built-in design partner. ### Company and Leadership [Notch](https://www.notch.cx) was founded in May 2021 by Rafael Broshi (CEO), Elool Jacoby (CPO), and Yuval Peled (CTO). The three met in the Israeli Air Force and have worked together for over a decade. The company is headquartered in New York with development centers in Israel. Total raised to date: $45 million. ARR grew 12x over the past 12 months. ### Problem and Opportunity Regulated industries spend $15-$30+ per customer support ticket, compared to $2-$5 in retail. The cost is high because every interaction carries compliance risk: wrong answer on a claim, missed disclosure requirement, misrouted document. Generic AI chatbots can’t handle these constraints. Most either hallucinate or require so many human checkpoints that the efficiency gains disappear. ### Product and Technology Notch built what it calls an AI operating system for regulated industries. The platform deploys autonomous agents for both customer-facing workflows (claims intake, policy questions) and back-office operations (document processing, data extraction, routing). What sets it apart is a layered governance architecture: conversation safety checks, identity-tied access rules, deterministic business limits, and jurisdiction-aware regulation enforcement. A Policy Engine encodes standard operating procedures and compliance guardrails into what the team describes as a “digital cage” for AI. The system was originally built as an internal operating layer for a specialty insurance product before pivoting to a broader platform. ### Use of Proceeds and Vision Funds will accelerate US expansion in insurance and financial services, deepen workflow coverage, and build out multi-agent orchestration capabilities. The target state: one underwriter overseeing 200 accounts with AI handling day-to-day operations. ### Market Context The AI customer experience market in regulated sectors represents a multi-hundred-billion-dollar opportunity. The 12x ARR growth suggests Notch is finding product-market fit at a pace that justifies the Series A size. Competition exists from horizontal AI platforms, but few are purpose-built for compliance-heavy environments. ## 4. Trayd Raises $10M For Construction Back-Office Automation ### Deal Overview - **Stage:** Series A - **Sector:** SaaS / Construction Tech - **Geography:** New York, NY - **Round Size:** $10M - **Valuation:** Not disclosed ### Investor Profile Investor details for this round were not publicly disclosed. The $10 million raise is modest relative to the other deals this week, but Series A sizing in construction tech tends to run smaller given longer sales cycles and the industry’s conservative adoption curve. ### Company and Leadership [Trayd](https://www.trayd.co) is a New York-based construction tech startup focused on back-office automation. The company closed its Series A on March 25, 2026. ### Problem and Opportunity Construction companies run on paper-heavy administrative processes. Payroll, compliance documentation, certified payroll reporting, and workforce tracking are manual, error-prone, and time-consuming. Subcontractors and general contractors alike lose hours each week to administrative tasks that haven’t been modernized the way project management or design tools have. ### Product and Technology Trayd builds a back-office automation platform for the construction industry. The product digitizes and streamlines the administrative workflows that sit behind the jobsite, from workforce documentation to payroll processing. ### Use of Proceeds and Vision The $10 million will be used to scale the platform and expand Trayd’s customer base across the construction industry. ### Market Context Construction is one of the least digitized industries in the global economy. While project management tools like Procore have gained traction on the jobsite, back-office operations remain largely untouched by modern software. That gap creates a real opening for vertical SaaS players willing to build for the industry’s specific compliance and workflow requirements. ## Lessons For Founders - **Regulation is a feature, not a bug.** Three of four deals this week involve heavily regulated industries (healthcare, insurance, financial services). Building for compliance requirements creates natural moats that horizontal AI platforms struggle to cross. If your space has complex rules, lean into them. - **The $500K-to-$80M jump is possible with the right distribution.** Latent Health went from a YC pre-seed to an $80 million Series A by signing 50% of the top 20 US health systems. Enterprise distribution at that scale compresses fundraising timelines and expands round sizes. - **Employer-sponsored models unlock different economics.** eMed’s $200 million raise is built on selling to employers rather than consumers. B2B2C distribution through employers provides predictable revenue, richer data, and higher willingness to pay than direct-to-consumer alternatives. - **12x ARR growth speaks louder than any pitch deck.** Notch’s 12x revenue growth over 12 months attracted a $30 million round with top-tier investors. At Series A, demonstrated traction in a defined market segment outweighs TAM slides and vision narratives every time.